ELOXX PHARMACEUTICALS, INC. Stock Issued During Period, Value, New Issues
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- ELOXX PHARMACEUTICALS, INC. stock issued during period, value, new issues for the quarter ending 2021-06-30 was $47.72M.
- ELOXX PHARMACEUTICALS, INC. stock issued during period, value, new issues for the quarter ending 2018-09-30 was $0.00, a 100.00% decline year-over-year.
- ELOXX PHARMACEUTICALS, INC. stock issued during period, value, new issues for the quarter ending 2017-09-30 was $1.50M.
- ELOXX PHARMACEUTICALS, INC. stock issued during period, value, new issues for the quarter ending 2016-06-30 was $0.00.
- ELOXX PHARMACEUTICALS, INC. stock issued during period, value, new issues for fiscal 2017 was $17.01M.
- ELOXX PHARMACEUTICALS, INC. stock issued during period, value, new issues for fiscal 2016 was $1.15M, a 76.13% decline from fiscal 2015.
- ELOXX PHARMACEUTICALS, INC. stock issued during period, value, new issues for fiscal 2015 was $4.83M.
- ELOXX PHARMACEUTICALS, INC. stock issued during period, value, new issues for fiscal 2013 was $4.04M, a 25.30% increase from fiscal 2012.
| Period end | Stock Issued During Period, Value, New Issues 3 month | Stock Issued During Period, Value, New Issues 12 month |
|---|---|---|
| 2021-06-30 | $47.72M 10-Q · filed 2022-11-10 | |
| 2018-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-08 | |
| 2017-12-31 | $17.01M 10-K · filed 2020-03-06 | |
| 2017-09-30 | $1.50M 10-Q · filed 2017-11-14 | |
| 2016-06-30 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2017-10-13 | $1.15M 10-K · filed 2017-10-13 |
| 2016-03-31 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2016-05-12 | |
| 2015-12-31 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2016-02-16 | |
| 2015-09-30 | $1.15M 10-Q · filed 2015-11-16 | |
| 2015-06-30 | $4.83M 10-K · filed 2017-10-13 | |
| 2013-09-30 | $0.00 10-Q · filed 2013-11-14 | |
| 2013-06-30 | $4.04M 10-K · filed 2015-10-09 | |
| 2012-12-31 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2013-02-14 | $2.82M derived: sum of 4 quarters · filed 2014-09-29 |
| 2012-09-30 | $100.57K 10-Q · filed 2012-11-14 | $2.85M derived: sum of 4 quarters · filed 2014-09-29 |
| 2012-06-30 | -$139.35K derived: 10-K 12 month − 10-Q 9 month · filed 2014-09-29 | $3.23M 10-K · filed 2014-09-29 |
| 2012-03-31 | $2.86M derived: 10-Q 9 month − 10-Q 6 month · filed 2012-05-14 | |
| 2011-12-31 | $23.88K derived: 10-Q 6 month − 10-Q 3 month · filed 2012-02-14 | |
| 2011-09-30 | $481.37K 10-Q · filed 2011-11-14 | |
| 2011-06-30 | $1.85M 10-K · filed 2013-09-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| Tevogen Inc. (TVGN) | United States | $0.049B |